Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Andrew J Schoenfeld, M.D.

Co-Author

This page shows the publications co-authored by Andrew Schoenfeld and John Shin.
Connection Strength

2.908
  1. A Natural History of Patients Treated Operatively and Nonoperatively for Spinal Metastases Over 2?Years Following Treatment: Survival and Functional Outcomes. Spine (Phila Pa 1976). 2022 04 01; 47(7):515-522.
    View in: PubMed
    Score: 0.249
  2. Evaluating frailty, mortality, and complications associated with metastatic spine tumor surgery using machine learning-derived body composition analysis. J Neurosurg Spine. 2022 Feb 25; 1-11.
    View in: PubMed
    Score: 0.247
  3. Characterizing Health-Related Quality of Life by Ambulatory Status in Patients with Spinal Metastases. Spine (Phila Pa 1976). 2022 Jan 15; 47(2):99-104.
    View in: PubMed
    Score: 0.245
  4. The effectiveness of systemic therapies after surgery for metastatic renal cell carcinoma to the spine: a propensity analysis controlling for sarcopenia, frailty, and nutrition. J Neurosurg Spine. 2021 Jun 25; 1-10.
    View in: PubMed
    Score: 0.236
  5. Performance assessment of the metastatic spinal tumor frailty index using machine learning algorithms: limitations and future directions. Neurosurg Focus. 2021 05; 50(5):E5.
    View in: PubMed
    Score: 0.234
  6. Prospective comparison of the accuracy of the New England Spinal Metastasis Score (NESMS) to legacy scoring systems in prognosticating outcomes following treatment of spinal metastases. Spine J. 2022 01; 22(1):39-48.
    View in: PubMed
    Score: 0.232
  7. Clinician Experiences in Treatment Decision-Making for Patients with Spinal Metastases: A Qualitative Study. J Bone Joint Surg Am. 2021 Jan 06; 103(1):e1.
    View in: PubMed
    Score: 0.228
  8. Survival After Surgery for Renal Cell Carcinoma Metastatic to the Spine: Impact of Modern Systemic Therapies on Outcomes. Neurosurgery. 2020 11 16; 87(6):1174-1180.
    View in: PubMed
    Score: 0.226
  9. Predicting tumor-specific survival in patients with spinal metastatic renal cell carcinoma: which scoring system is most accurate? J Neurosurg Spine. 2020 Jun 05; 1-11.
    View in: PubMed
    Score: 0.219
  10. Prospective validation of a clinical prediction score for survival in patients with spinal metastases: the New England Spinal Metastasis Score. Spine J. 2021 01; 21(1):28-36.
    View in: PubMed
    Score: 0.215
  11. Design of the prospective observational study of spinal metastasis treatment (POST). Spine J. 2020 04; 20(4):572-579.
    View in: PubMed
    Score: 0.211
  12. Laboratory markers as useful prognostic measures for survival in patients with spinal metastases. Spine J. 2020 01; 20(1):5-13.
    View in: PubMed
    Score: 0.204
  13. Spinal metastases 2021: a review of the current state of the art and future directions. Spine J. 2021 09; 21(9):1414-1429.
    View in: PubMed
    Score: 0.058
  14. Predicting 90-Day and 1-Year Mortality in Spinal Metastatic Disease: Development and Internal Validation. Neurosurgery. 2019 10 01; 85(4):E671-E681.
    View in: PubMed
    Score: 0.052
  15. Development of Machine Learning Algorithms for Prediction of 30-Day Mortality After Surgery for Spinal Metastasis. Neurosurgery. 2019 07 01; 85(1):E83-E91.
    View in: PubMed
    Score: 0.051
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.